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Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder characterized by its heterogeneous clinical evolution.
Despite the discovery of themost frequent cytogenomic drivers of disease during the last decade, new efforts are needed in order to
improve prognostication. In this study, we used gene expression data of CLL samples in order to discover novel transcriptomic
patterns associated with patient survival. We observed that a 3-gene expression signature composed of SCGB2A1, KLF4, and
PPP1R14B differentiate a group of circa 5% of cases with short survival. .is effect was independent of the main cytogenetic
markers of adverse prognosis. Finally, this finding was reproduced in an independent retrospective cohort. We believe that this
small gene expression pattern will be useful for CLL prognostication and its association with CLL response to novel drugs should
be explored in the future.
1. Introduction
Chronic lymphocytic leukemia (CLL) is the most frequent
lymphoproliferative syndrome in western populations, and
it is characterized by its remarkable heterogeneous clinical
evolution. In the molecular era of medicine, the discovery of
new biomarkers is a central issue of disease prognostication.
Recurrent cytogenetic aberrations, the IGHV hypermutation
status, and, more recently, somatic mutations in driver genes
such as TP53, ATM, NOTCH1, SF3B1, MYD88, and BIRC3
have improved risk stratification of CLL patients [1–3].
.e inherent continuous nature of gene expression
supposes an opportunity to dissect heterogeneous tumor
types into comprehensive molecular subclasses. Indeed,
previous efforts have proven the usefulness of this approach
in CLL prognostication. Rodr´ıguez et al. reported a seven-
gene signature correlated with IGHV mutation status that
predicts time to treatment [4], whereas Herold et al. reported
an 8-gene prognostic signature that predicted overall
survival, but the predictability of this pattern was not su-
perior to that of the combination of conventional FISH and
IGHV mutation status [5].
.us, we reasoned that the identification of new and
small-sized patterns of gene expression associated with
adverse survival and their dependency on the main cyto-
genomic factors of adverse prognosis may improve CLL
prognostication.
2. Methods
We used two public databases of gene expression data in CLL
patients in order to create a training and a validation cohort.
.e training cohort was composed of transcriptomic data
from 450 CLL cases enrolled in the International Cancer
Genome Consortium (data accessible in the European Ge-
nome-phenome Archive, accession code EGAD00010000875).
Samples were collected and analyzed by the aforementioned
consortium before initiation of any treatment. Overall survival
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was calculated as time fromCLL diagnosis to time of death from
any cause. Transcriptomic data were measured with Affymetrix
HG-u219 microarrays. .e Robust Multichip Algorithm (RMA)
[6] was used to preprocess, normalize, and log2-transform
expression data. For genes targeted by multiple probes, the
median value was extracted. For each gene, we determined its
individual clusterization capacity. .eMclust [7] algorithm was
used in order to detect the 2 most likely patient clusters
according to the expression of each gene (Mclust function,
parameter G� 2). Briefly, the Mclust algorithm determines the
most likely set of clusters according to geometric properties
(distribution, volume, and shape). An expectation-maximiza-
tion algorithm is used for maximum likelihood estimation, and
the best model is selected according to Bayes information cri-
teria. .e association of each of these single-gene clusters with
overall survival was calculated using cox regression. .ereafter,
those genes whose clusterization was significantly associated
with survival (q-value <0.05) were selected for multivariate
clusterization using the same Mclust algorithm.
An independent cohort of 107 CLL samples was used for
validation (accessible in the Gene Expression Omnibus,
accession code GSE22762, array platform Affymetrix Hu-
man Genome U133 Plus 2.0 Array). .is dataset was
composed of samples from patients with newly diagnosed
and preexisting CLL, a fraction of whom had been pre-
viously treated. Overall survival was calculated as the period
of time from microarray analysis to death from any cause.
Briefly, normalized gene expression estimates were
extracted, median expression for multiprobe genes was
calculated, and the array platform batch effect was adjusted
using Combat [8]. .en, cluster prediction was performed
with parameters estimated in the training cohort, and cox
regression was used to verify the association of this clus-
terization with survival.
3. Results
.ree transcripts were able to individually clusterize patients
in two groups with significantly different survival in the
study cohort (Benjamini–Hochberg q-value <0.05) (Sup-
plementary Figure 1 and Supplementary Table 1). .ese
genes were SCGB2A1, KLF4, and PPP1R14B. A multivariate
clusterization based on the three genes was created using
Mclust. According to the BIC, the geometrical model ren-
dering the optimal clusterization was diagonal, with varying
volume and equal shape (VEI in Mclust argot). .is clus-
terization was markedly associated with overall survival (cox
regression p-value 4.31× 10− 6, hazard ratio 4.86, lower 95%
confidence interval 2.48, upper 95% confidence interval 9.53;
Figures 1(a) and 2(a)). .e cluster of patients with adverse
survival supposed 4.22% of the study cohort. .e prognostic
impact of this clusterization on survival was validated in an
independent cohort (cox regression p-value 5.7×10− 6,
hazard ratio 10.79, lower 95% confidence interval 3.86,
upper 95% confidence interval 30.17; Figures 1(b) and 2(b);
Supplementary Table 2). .e cluster of patients with adverse
survival represented 5.60% of the validation cohort. We
could visually detect one case in validation cohort whose
probability of belonging to the small cluster was 52.79%
(indicated with an asterisk in Figure 2(b)). Discarding this
event from the survival analysis did not significantly change
the results: p-value 6.31× 10− 6; 95% HR: 0.03–0.26.
In order to assess the independence of our clusterization
approach, we used data from Puente et al. [1] to analyze for
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Figure 1: Kaplan–Meier plots representing the different evolution of CLL patients belonging to the two different clusters in the (a) training
and (b) validation cohorts.
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potential confounders in the study cohort. .e following
covariates were included in the model: patient’s age at di-
agnosis, Binet stage at diagnosis, IGHV mutation status,
presence of TP53 mutation or 17p deletion, ATM mutation
or 11q deletion, NOTCH1 mutation, SF3B1 mutation, and
BIRC3 mutation. .e association of the transcriptome
clusterization remained significant independently of the
effect of these adverse prognostic factors (cox regression
p-value 8.95×10− 3, hazard ratio 2.76). Since we could not
get access to the status of these markers in the validation
cohort, we could not reproduce this finding.
4. Discussion
In this paper, we present a new gene expression signature
that identifies a group of CLL patients with shorter survival.
.e signature was composed of the following genes: KLF4,
SCGB2A1, and PPP1R14B. KLF4 belongs to the Kruppel
family of transcription factors. KLF4 has both growth
suppressive and antiapoptotic functions since it can trigger
cell-cycle arrest by inducing TP53-mediated expression of
CDKN1A and it can also block apoptosis by inhibiting TP53
activity and suppressing BAX expression [9]. Less is known
about SCGB2A1 and PPP1R14B. SCGB2A1 encodes a gene of
the secretoglobin family. SCGB2A1 is highly expressed in
some tumor types [10], and it has been linked to adverse
cancer prognosis in others [11]. PPP1R14B encodes a pu-
tative inhibitor of protein phosphatase 1, a pleiotropic
enzyme that plays multiple functions in cellular growth, cell-
cycle regulation, and apoptosis [12].
Patients from both cohorts were diagnosed and treated
in the era of chemoimmunotherapy. A limitation of this
analysis is that we ignore which treatment regimens (if any)
were administered to each patient. Nevertheless, the re-
markable strong association of the reported clusterization
with overall survival in both the training and validation
cohorts suggests a treatment-independent mechanism. It
will be important to study the impact of new targeted drugs
such as tyrosine kinase inhibitors or BCL2 antagonists in the
survival of these CLL cases.
In conclusion, we report a 3-gene expression signature
that identifies a subgroup ∼5% of CLL patients with short
survival before the era of tyrosine kinase inhibitors. Fur-
thermore, this clusterization in the training cohort was
associated with adverse outcome independently of the most
important cytogenomic factors.
5. Conclusions
A 3-gene expression signature characterizes a group of circa
5% of CLL patients with short survival..e prognostic impact
of this signature was independent of the main cytogenomic
markers of adverse prognosis at least in the study cohort. .is
small signature might be useful for future studies about
disease prognostication and drug response in CLL.
Data Availability
.is study used public data accessible in the Gene Ex-
pression Omnibus and in the repository of the International
Cancer Genome Consortium.
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Figure 2: Scatterplot matrix representing the relationship of patients according to the expression of SCGB2A1, KLF4, and PPP1R14B.
Separate plots are provided for the training (a) and validation (b) cohorts. Points are labeled according to the cluster assignation: black dots
represent patients in the cluster of adverse prognosis and red dots represent the remaining group of patients. In (b), the asterisk indicates an
event near the limit of both clusters (see text).
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Additional Points
A 3-gene expression signature identifies a subgroup of pa-
tients with chronic lymphocytic characterized by short
survival. .e classifier was independent of the main cyto-
genomic predictors of adverse prognosis in the study cohort.
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Supplementary Materials
Supplementary Figure 1: individual patient clusterization
according to the expression of the three selected genes in the
training cohort (red and blue bars). Black bars represent
gene expression for each patient in the cohort. Supple-
mentary Table 1: expression levels of SCGB2A1, KLF4, and
PPP1R14B, survival data, and cluster membership of pa-
tients in the training cohort. Supplementary Table 2: ex-
pression levels of SCGB2A1, KLF4, and PPP1R14B, survival
data, and cluster membership of patients in the validation
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